MARKET

AWH

AWH

Aspira Womens Health Inc
NASDAQ
3.100
-0.330
-9.62%
Closed 16:00 03/28 EDT
OPEN
3.675
PREV CLOSE
3.430
HIGH
3.675
LOW
2.910
VOLUME
38.69K
TURNOVER
0
52 WEEK HIGH
6.75
52 WEEK LOW
2.309
MARKET CAP
32.04M
P/E (TTM)
-1.5197
1D
5D
1M
3M
1Y
5Y
Aspira Women’s Health GAAP EPS of -$0.30 beats by $0.15, revenue of $2.13M misses by $0.42M
Aspira Women’s Health GAAP EPS of -$0.30 beats by $0.15, revenue of $2.13M misses by $ 0.42M. The company announced its fourth quarter results after the market closed on Tuesday. Aspira women's health now has a market value of $1.1 billion.
Seeking Alpha · 14h ago
AWH Stock Earnings: Aspira Womens Health Beats EPS, Misses Revenue for Q4 2023
Aspira Womens Health reported earnings per share of -30 cents for the fourth quarter of 2023. The company reported revenue of $2.13 million. This was 16.14% worse than the analyst estimate for revenue in the same period of time.
Investorplace · 18h ago
Aspira Women's Health Inc reports results for the quarter ended in December - Earnings Summary
Aspira Women's Health Inc reported a quarterly adjusted loss of 30 cents per share for the quarter ended in December. Revenue fell 1.1% to $2.13 million from the same quarter last year. The company reported a loss of $3.09 million.
Reuters · 20h ago
Aspira Womens Health Q4 EPS $(0.30) Beats $(0.45) Estimate, Sales $2.13M Miss $2.54M Estimate
Aspira Womens Health reported quarterly losses of $0.30 per share. The company also reported quarterly sales of $2.13 million. Aspira beat the analyst consensus estimate by 33.33%. The company is up 45.45 percent in the past week.
Benzinga · 22h ago
*Aspira Women's Health 4Q Loss/Shr 30c >AWH
Dow Jones · 22h ago
*Aspira Women's Health 4Q Rev $2.13M >AWH
Dow Jones · 22h ago
Press Release: Aspira Women's Health Reports -2-
This press release contains forward-looking statements. These statements involve a number of risks and uncertainties. Actual results could differ from those discussed due to known and unknown risks, uncertainties, and other factors. Aspira Women's Health's offering is expected to close in the near future.
Dow Jones · 22h ago
*Aspira Women's Health 4Q Loss $3.1M >AWH
Dow Jones · 22h ago
More
About AWH
Aspira Women's Health Inc. is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. Its products include Ova1, Overa, Ova1Plus and OvaWatch. Ova1 is a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy. Overa is a biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity. Ova1Plus is a reflex offering, which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results. OvaWatch is a lab developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass. The Company’s products are distributed through its own national sales force, through its decentralized testing platform.

Webull offers Aspira Women's Health Inc stock information, including NASDAQ: AWH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AWH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AWH stock methods without spending real money on the virtual paper trading platform.